Search Results 481-490 of 16633 for alopecia

1. A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer - Mayo Clinic

   alopecia. Exclusion Criteria: - Tumors in the breast or bone - Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy ...

2. Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 ...

3. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   0) ≤ Grade 1, or to the levels dictated in the eligibility criteria with the exception of alopecia. Patient with history of confirmed progressive ...

4. Membership - Center for Multiple Sclerosis and Autoimmune Neurology - Mayo Clinic Research

   Faculty members conducting research through the Center for Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic have wide-ranging expertise.

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

6. Hairy cell leukemia - Doctors and departments - Mayo Clinic

   This slow-growing cancer doesn't always need immediate treatment. When hairy cell leukemia treatment is needed, it usually starts with chemotherapy.

7. Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin - Mayo Clinic

   NOTE: Patients with ≤ Grade 2 neuropathy or having any alopecia are an exception to this criterion and may qualify for the study. NOTE: If patient received ...

8. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Note: except Neuropathy Grade ≤ 2, any grade alopecia, or bone marrow parameters [any of Grade 1 or 2 permitted if directly related to bone marrow involvement] ...

9. Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying - Mayo Clinic

   Inclusion Criteria: Able to provide written consent; No medical problems or chronic diseases, specifically, no type 2 diabetes mellitus; Body Mass Index of ...

10. Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides - Mayo Clinic

    ... alopecia and ≤Grade 2 peripheral neuropathy. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (Appendix B). Life expectancy ≥12 weeks ...